Proceedings: Rationale and results of primary endocrine therapy in patients with prostatic cancer.
D000726:Androgen Antagonists; D000818:Animals; D001119:Arginase / Q000378:metabolism; D001835:Body Weight; D002369:Castration; D003520:Cyclophosphamide / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009929:Organ Size; D010088:Oxidoreductases / Q000378:metabolism; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D051381:Rats
D000726:Androgen Antagonists; D003520:Cyclophosphamide; D004247:DNA; D003534:Cyproterone; D010088:Oxidoreductases; D001119:Arginase; D005472:Fluorouracil